You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

AML with MDS related changes

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Acute Myelogenous Leukemia (AML) Due to Therapy, Acute Myeloid Leukemia With Myelodysplasia-Related Changes Trial in La Jolla,

Recruiting
  • Acute Myelogenous Leukemia (AML) Due to Therapy
  • Acute Myeloid Leukemia With Myelodysplasia-Related Changes
  • Orange, California
  • +2 more
Nov 30, 2022

Acute Myeloid Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia, Chronic Myelomonocytic Leukemia Trial in Chapel

Recruiting
  • Acute Myeloid Leukemia
  • +5 more
  • Biospecimen Collection
  • +3 more
  • Baltimore, Maryland
  • +2 more
Jan 19, 2023

iN the Real Practice

Not yet recruiting
  • Acute Myeloid Leukemia (AML)
  • +2 more
  • Vyxeos liposomal
  • Roma, Italy
    Policlinico Tor Vergata
Nov 16, 2023

Acute Myeloid Leukemia, MDS, Myeloid Malignancies Trial in Boston (Decitabine, Filgrastim)

Not yet recruiting
  • Acute Myeloid Leukemia
  • +6 more
  • Boston, Massachusetts
  • +1 more
Mar 31, 2023

Acute Myeloid Leukemia, MDS, Transplant-Related Hematologic Malignancy Trial in Milano (Fludarabine, ARA-C, Treosulfan)

Completed
  • Acute Myeloid Leukemia
  • +2 more
  • Milano, Lombardia, Italy
    Ospedale San Raffaele
Jul 18, 2022

Disorder Related to Bone Marrow Transplantation, Leukemia, Transplantation Infection Trial in Houston (Fludarabine, Clofarabine,

Completed
Has Results
  • Disorder Related to Bone Marrow Transplantation
  • +2 more
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Nov 18, 2021

AML - Acute Myeloid Leukemia, MDS (Myelodysplastic Syndrome), Mixed Phenotype Acute Leukemia Trial in Palo Alto (T-allo10)

Recruiting
  • AML - Acute Myeloid Leukemia
  • +5 more
  • T-allo10
  • Palo Alto, California
    Lucile Packard Children's Hospital
Feb 2, 2022

AML/MDS, Acute Myeloid Leukemia, MDS Trial (Danvatirsen, Danvatirsen + Venetoclax)

Not yet recruiting
  • AML/MDS
  • +2 more
  • (no location specified)
Aug 14, 2023

Myelodysplastic Syndrome, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute Trial in Worldwide (Azacitidine,

Active, not recruiting
Has Results
  • Myelodysplastic Syndrome
  • +2 more
  • Daphne, Alabama
  • +241 more
Dec 23, 2022

MDS, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute Trial in Worldwide (Azacitidine, Pevonedistat)

Completed
Has Results
  • Myelodysplastic Syndromes
  • +2 more
  • Birmingham, Alabama
  • +58 more
Aug 24, 2022

Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in France, United States (SY-1425 (tamibarotene), azacitidine,

Active, not recruiting
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndrome
  • SY-1425 (tamibarotene)
  • +2 more
  • Hartford, Connecticut
  • +25 more
May 4, 2022

Acute Myeloid Leukemia, Advanced MDS Trial in New York (Busulfan, Melphalan, Fludarabine, Anti-Thymocyte Globulin, Palifermin,

Completed
Has Results
  • Acute Myeloid Leukemia
  • Advanced Myelodysplastic Syndromes
  • Busulfan, Melphalan, Fludarabine, Anti-Thymocyte Globulin, Palifermin, Stem cell transplant
  • New York, New York
    Memorial Sloan-Kettering Cancer Center
Aug 27, 2021

AML/MDS Trial in United States (Mana 312)

Active, not recruiting
  • AML/MDS
  • Mana 312
  • Denver, Colorado
  • +7 more
Jun 13, 2022

Refractory Acute Myeloid Leukemia, Relapsed Acute Myelomonocytic Leukemia, MDS Trial in Cleveland (CPX-351)

Recruiting
  • Refractory Acute Myeloid Leukemia
  • +2 more
  • Cleveland, Ohio
    Cleveland Clinic, Case Comprehensive Cancer Center
Mar 15, 2022

Acute Myeloid Leukemia, MDS Trial in Nashville, San Antonio (biological, drug, procedure)

Terminated
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndromes
  • rivogenlecleucel
  • +3 more
  • Nashville, Tennessee
  • +1 more
Nov 11, 2020

Leukemia, Myeloid, Acute, MDS Trial in Worldwide (Azacitidine, Durvalumab)

Active, not recruiting
Has Results
  • Leukemia, Myeloid, Acute
  • Myelodysplastic Syndromes
  • New Haven, Connecticut
  • +94 more
Jun 9, 2022

Acute Myeloid Leukemia, MDS, Chronic Myelomonocytic Leukemia Trial in Canada, United States (CFI-400945, Azacitidine,

Recruiting
  • Acute Myeloid Leukemia
  • +5 more
  • Duarte, California
  • +7 more
Jul 20, 2022

Acute Myeloid Leukemia, MDS Trial in Hangzhou (Decitabine for Injection, VENCLYXTO)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndromes
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, College of Medicine, Zhejiang Uni
Sep 18, 2023

AML, MDS Trial in United States (APVO436)

Recruiting
  • AML
  • MDS
  • APVO436
  • San Francisco, California
  • +11 more
Feb 8, 2022

MDS, Myeloid Leukemia, Allogeneic Stem Cell Transplantation Trial in Pittsburgh (IFN-? (interferon gamma-1b) injection)

Recruiting
  • Myelodysplastic Syndromes
  • +2 more
  • IFN-γ (interferon gamma-1b) injection
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Jan 5, 2023

AML, Adult Trial (STI-8591)

Not yet recruiting
  • AML, Adult
  • (no location specified)
Jul 12, 2023

Acute Myeloid Leukemia, Myelodysplasia Trial in United States (MGTA-117)

Recruiting
  • Acute Myeloid Leukemia
  • Myelodysplasia
  • MGTA-117
  • Duarte, California
  • +7 more
Nov 23, 2022

Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Hematopoietic Stem Cell Transplant (HSCT) Trial in Pittsburgh

Active, not recruiting
  • Acute Myeloid Leukemia (AML)
  • +2 more
  • Reduced-Intensity Conditioning Regimen
  • Myeloablative Conditioning Regimen
  • Pittsburgh, Pennsylvania
    UPMC Children's Hospital of Pittsburgh
Jan 4, 2023

Acute Myelogenous Leukemia, Myelodysplastic Syndrome Trial in Valhalla (Gemtuzumab Ozogamicin)

Active, not recruiting
  • Acute Myelogenous Leukemia
  • Myelodysplastic Syndrome
  • Gemtuzumab Ozogamicin
  • Valhalla, New York
    New York Medical College
Sep 26, 2022

Cancer, MDS-EB, MDS Trial in Athens, Southampton, Sheffield (INKmune)

Recruiting
  • Cancer
  • +4 more
  • INKmune
  • Athens, Attiki, Greece
  • +2 more
Jul 3, 2023